Discontinuation and Management of Levetiracetam in Brain Tumor Patients

Indications for Immediate Discontinuation

Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome) require immediate cessation of levetiracetam and must never be continued. 1
When DRESS syndrome is suspected, prompt drug withdrawal is essential to avoid life‑threatening complications. 2

Levetiracetam should be tapered gradually over several weeks to reduce the risk of breakthrough seizures; abrupt cessation is discouraged in non‑emergency contexts. 3

Clinical Scenario	Recommendation	Evidence
Primary seizure prophylaxis (patient has never seized)	Discontinue levetiracetam once local tumor control is achieved because prophylaxis is not indicated.	NCCN (JNCCN 2011) & Annals of Oncology 2021 [3][4]
Secondary seizure prophylaxis (patient has had seizures)	Continue levetiracetam until local tumor control is confirmed; then consider a gradual taper.	NCCN (JNCCN 2011) & Annals of Oncology 2021 [3]
Monitoring during taper	Watch for increased seizure frequency, which may signal tumor progression; obtain repeat MRI if seizures worsen.	NCCN (JNCCN 2011) [4]

Lamotrigine – Excellent tolerability; requires several weeks to reach therapeutic levels before full seizure control. 3
Valproic acid – Effective and generally well tolerated; contraindicated in women of child‑bearing potential. 3

Enzyme‑inducing agents such as phenytoin, carbamazepine, and phenobarbital should be avoided because of significant drug‑interaction potential and adverse effect profiles. [3][4]

If levetiracetam‑induced behavioral or psychiatric symptoms markedly impair quality of life or safety, switch to an alternative antiepileptic (e.g., lamotrigine or valproic acid). [3][4]

In patients who have undergone near‑total surgical resection of a brain tumor and have no evidence of recurrent disease, tapering and discontinuation of levetiracetam can be initiated within weeks after surgery. 5
When only a biopsy or partial resection has been performed and subsequent radiotherapy or chemotherapy achieves tumor regression, a gradual reduction and eventual discontinuation of levetiracetam may be considered. 5
Patients with brain‑tumor‑related seizures who are not surgical candidates should continue secondary seizure prophylaxis until local tumor control is confirmed. 5

At every follow‑up visit, clinicians should inquire about any breakthrough seizures in patients with a history of brain tumor–related epilepsy. 5
Serum levetiracetam levels may be measured to evaluate treatment failure, assess adherence, and help differentiate drug‑related adverse effects from other causes. 5
A worsening of pre‑existing seizure activity can be an early indicator of tumor progression; therefore, repeat MRI and appropriate ancillary studies (e.g., blood, CSF analyses) should be ordered when seizure control declines. 6

A slow, gradual taper of levetiracetam is recommended to maximize favorable outcomes and minimize the need for alternative interventions. 7

Patients and their caregivers should receive clear instructions on how to respond to breakthrough seizures and which healthcare contacts to reach in such events. 5

If any complications arise or seizure control deteriorates during the taper, a neurology consultation should be obtained promptly. 5